
A Colorful Cornucopia of Brain Benefits
Dr. Pamela Maher from The Salk Institute for Biological Studies, La Jolla, California has been studying fisetin for two decades. Her team's work has shown this remarkable antioxidant crosses the blood brain barrier. Once in the brain, it is. . .- Neuroprotective -- shields nerve cells from multiple toxic insults
- Neurotrophic -- promotes the growth of neurons while slowing their death
- An antioxidant -- induces the production of a variety of endogenous antioxidants, in particular glutathione, a key antioxidant enzyme system that protects against damage from free radicals
- Anti-inflammatory
- Memory boosting -- enhances learning and memory, including long-term memory
- Immune modifying -- positively influences pathways of the innate immune system that are involved in the progression of Alzheimer's
- Protective against Alzheimer's by reducing the brain cell damage caused by amyloid plaques and limiting the accumulation of tau tangles that cause the death of brain cells
- Reduces the impact of Huntington's disease, a rare, inherited brain disease.
Reverses Memory Loss in Animal Studies
The Salk team had already tested the new version, called CMS121, and found it was effective at slowing the degeneration of brain cells and improving the memory of mice. Following that, it was time for a bigger test using mice specially engineered to get the human equivalent of Alzheimer's. Some would get the drug while another group would not receive it. A third acted as healthy controls. The scientists tried to replicate how a middle-aged patient might be treated. So at nine months, the equivalent of middle age in mice, when the mice were already beginning to develop learning and memory problems, the researchers gave the active group daily doses of CMS121. Three months later, all groups were given a battery of cognitive and behavioral tests. The result of their experiment was that the Alzheimer's mice taking the drug saw their memory improve. They performed just as well as the healthy control rodents. But the untreated Alzheimer's mice performed poorly. In subsequent pathology analysis, the researchers discovered that the drug reduced neuro-inflammation. In addition, fat molecules called lipids, which play important roles in every cell in the body, differed in the mentally impaired mice who were not taking CMS121.FASN - Exciting New Alzheimer's Target
In particular, the non-drug Alzheimer's group had higher levels of lipid peroxidation, the process by which free radicals damage lipids in cell membranes. "That not only confirmed that lipid peroxidation is altered in Alzheimer's, but that this drug is actually normalizing those changes," said GamzeAtes, a member of the research team. To discover why this occurred, additional research showed CMS121 lowered levels of fatty acid synthetase (FASN), an enzyme that can promote lipid peroxidation. To see if this happens in humans, they examined brain samples of people who had died of Alzheimer's. Sure enough, they had higher levels of FASN compared to people of the same age who were cognitively healthy when they died. Dr. Maher, who led the team, said that "identifying a new target...is really exciting and opens a lot of doors."Why CMS121 Was Developed:
While fisetin, a natural flavonoid found in strawberries and other fruits, shows strong antioxidant and neuroprotective effects, it has:
Poor bioavailability
Limited brain penetration
CMS121 was engineered to:
Enhance blood-brain barrier penetration
Increase stability and potency
Mimic the longevity-promoting and brain-protecting effects seen in fisetin